Sullivan Lara 4
4 · Pyxis Oncology, Inc. · Filed Apr 4, 2022
Insider Transaction Report
Form 4
Sullivan Lara
DirectorPresident ,CEO & CMO
Transactions
- Award
Common Stock
2022-03-31+742,574→ 1,041,363 total
Footnotes (1)
- [F1]Represents restricted stock units that vest over a four-year period, with 25% vesting on the first anniversary of the grant date, and the remaining 75% vesting in 12 substantially-equal quarterly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.